Xiaobo Wang is listed as an executive officer and director on 2 SEC Form D filings by 1 issuer between Mar 2018 and Mar 2019: ACEA Therapeutics, Inc. (San Diego, CA — pharmaceuticals — 2018–2019; $18M reported sold to 6 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Feng Lin (2 shared filings), Jixun Lin (2 shared filings), Joyce Hsu (2 shared filings), Lin Li (2 shared filings), Mang Yu (2 shared filings) and 3 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Xiaobo. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for Xiaobo Wang and found 4 differences: Form D filed 18 days after the first sale; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.